The benefits of mass spectrometry for expediting biologics to patients
European Pharmaceutical Review
SEPTEMBER 20, 2023
Conversely, poor analytical characterisation will likely lead to questions from regulators and, without sufficient product and process knowledge, an IND or BLA that is eventually deemed incomplete. Incorrect DNA sequences can also lead to high levels of SVs. While SVs are typically present at less than 0.1
Let's personalize your content